Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report
Small-cell lung cancer (SCLC) remains a disease with poor prognosis, particularly in extensive-stage SCLC (ES-SCLC). Current standard-of-care treatment includes chemotherapy with platinum agents and etoposide plus immunotherapy with atezolizumab or durvalumab, which has achieved a mean overall survi...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2024-06-01
|
| Col·lecció: | Current Oncology |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1718-7729/31/7/271 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|